Provided are compositions and nanoparticle formulations that may be used, e.g., to deliver a therapeutic compound to a subject. In some embodiments, the nanoparticles may be used to deliver one or more chemotherapeutic agents to treat a cancer such, e.g., as a pancreatic ductal adenocarcinoma.

A polymeric compound is disclosed herein, having the general formula I: ##STR00001##
wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention are useful for the treatment and prevention of proliferative neoplastic and non-neoplastic diseases.

The present invention relates to a transdermal nano-carrier and, more specifically, to a nano-carrier having a chitosan-based nano-sponge structure. According to the present invention, as a nano-carrier having enhanced transdermal delivery on the basis of a complex containing chitosan is provided, it is possible to effectively deliver drugs, cosmetic materials, etc. into the skin.

The invention relates to self-assembled architectures formed from polymer-lipid blends, and in particular, to tubular and vesicular self-assembled architectures formed from polymer-lipid blends. The invention further relates to a method for forming the tubular and vesicular self-assembled architectures. The invention provides a composition comprising a lipid and an amphiphilic block copolymer, wherein the amphiphilic block copolymer is capable of undergoing self-assembly to form an architecture of a first geometry, wherein the composition undergoes self-assembly to form a bilayer architecture enclosing a volume of a second geometry, wherein the second geometry is different from that of the first geometry.

The present invention relates generally to vesicles such as liposomes, colloidosomes, and polymersomes, as well as techniques for making and using such vesicles. In some cases, the vesicles may be at least partially biocompatible and/or biodegradable. The vesicles may be formed, according to one aspect, by forming a multiple emulsion comprising a first droplet surrounded by a second droplet, which in turn is surrounded by a third fluid, where the second droplet comprises lipids and/or polymers, and removing fluid from the second droplet, e.g., through evaporation or diffusion, until a vesicle is formed. In certain aspects, the size of the vesicle may be controlled, e.g., through osmolarity, and in certain embodiments, the vesicle may be ruptured through a change in osmolarity. In some cases, the vesicle may contain other species, such as fluorescent molecules, microparticles, pharmaceutical agents, etc., which may be released upon rupture. Yet other aspects of the invention are generally directed to methods of making such vesicles, kits involving such vesicles, or the like.

This disclosure relates to polymersomes comprising a crosslinked polymer and their use as drug delivery vehicles. Specifically, polymersomes comprising a polymer of Formula I:

##STR00001##

wherein each R is independently C.sub.1-6 alkyl; and n is an integer between 1 and 50.

The present invention is directed to peptisomes, including nanopeptisomes, which have a perfluorocarbon liquid core containing a perfluorocarbon liquid and a cargo, such as a therapeutically active agent, dispersed in the perfluorocarbon, liquid, and a plurality of amphiphilic peptide molecules surrounding the perfluorocarbon liquid core, wherein the amphiphilic peptide is represented by Formula (I) HB-CL-HP wherein HB is a fluorinated hydrophobic block, such as a fluorinated hydrophobic amino acid sequence. CL is a cross-linking motif and HP is a hydrophilic amino acid sequence. The present invention is also directed to methods of use of the amphiphilic peptides and peptisomes, such as nanopeptisomes, to deliver a cargo, such as a therapeutically active agent, to a cell, Q wherein the cell may be in vitro, ex vi, or in vivo.

A nanolipogel is a delivery vehicle including one or more lipid layer surrounding a hydrogel core, which may include an absorbent such as a cyclodextrin or ion-exchange resin. Nanolipogels can be constructed so as to incorporate a variety of different chemical entities that can subsequently be released in a controlled fashion. These different incorporated chemical entities can differ dramatically with respect to size and composition. Nanolipogels have been constructed to contain co-encapsulated proteins as well as small hydrophobic drugs within the interior of the lipid bilayer. Agents incorporated within nanolipogels can be released into the milieu in a controlled fashion, for example, nanolipogels provide a means of achieving simultaneous sustained release of agents that differ widely in chemical composition and molecular weight. Additionally, nanolipogels can favorably modulate biodistribution.

Embodiments of the invention include plant stem cell products and treatment methods using the products. In some embodiments, the products may include extracts of plant stem cells, such as apple stem cells, and an aerosolizing device configured to create an aerosol from the plant stem cell products and to deliver the aerosol to the lung via inhalation. Treatment methods include aerosol inhalation of the plant stem cell products.